SYDNEY—Vaccine and blood-products company CSL on Tuesday unveiled a sweeping corporate restructure that will include spinning off its flu-vaccine unit Seqirus and cutting up to 15% of its staff.

CSL is laying off up to 15% of its workforce as the Australian pharma looks to cut R&D costs and spin out its vaccine subsidiary in a wide-ranging restructure. The Melbourne-headquartered company will ...

Macquarie Group Ltd (ASX: MQG) has downgraded CSL Ltd (ASX: CSL) shares. Let's find out why the broker has made the ...

CSL to downsize one-third of R&D division, AFR reports Company has not confirmed the number of job reductions Shares up 3% at over 6-week high July 15 (Reuters) - Australian biotech giant CSL Ltd (CSL ...

Thank you for standing by, and welcome to the CSL Limited Full Year Financial Results. [Operator Instructions] I would now like to hand the conference over to Mr. Chris Cooper, Head of Investor ...

CSL pays $117 million for exclusive option to acquire VarmX VarmX could receive up to $388 million if milestones are met CSL funds VarmX's Phase 3 trial for VMX-C001 Sept 16 (Reuters) - Australia's ...